Dow Jones
39.509,27 -3,57 (-0,01%) Nasdaq
16.395,80 +54,94 (+0,34%) Nikkei 225
38.179,46 -49,65 (-0,13%) EUR/USD
1,0800 +0,0028 (+0,26%) Bitcoin EUR
58.518,37 +1.391,15 (+2,44%) CMC Crypto 200
1.296,29 +36,09 (+2,86%)
CLRB May 2024 5.000 put
| Chiusura precedente | 1,7000 |
| Aperto | 1,7000 |
| Denaro | 1,8000 |
| Lettera | 0,0000 |
| Prezzo d'esercizio | 5,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,7000 - 1,7000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 59 |
GlobeNewswireCellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio. Cellectar has secured four patents across the key global regions Europe, Australia and Canada, covering the company’s proprietary Phospholipid Drug Conjug
- GlobeNewswire
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment optionsFLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines Agency (EMA) has granted Priority
- GlobeNewswire
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for th
